Abstract
Cardiovascular disease are among the principal causes of disability and death in older persons and therefore preventive interventions for such diseases are a high priority.Secondary prevention trials have established the efficacy of low dose aspirin for the prevention of cardiovascular disease (fatal , non-fatal myocardial infarction fatal or non-fatal stroke , or hospitalisation for heart failure). The benefits of low dose ASPRIN outweigh the risk of majorhaemorrhage (hemorrhagic stroke, symptomatic intracranial bleeding are clinically significant extra-cranial bleeding) associated with it in the secondary prevention of cardiovascular events. However, the role of low dose aspirin in primary prevention in elderly healthy individuals is unclear. JMS 2018;21(1):68-69
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
